Switching Sildenafil to Riociguat in Chronic Thromboembolic Pulmonary Hypertension After Balloon Pulmonary Angioplasty
This study was designed to investigate the safety and efficacy of replacing phosphodiesterase 5 inhibitors (PDE5i) with riociguat in patients with Chronic thromboembolic pulmonary hypertension (CTEPH) who have undergone pulmonary angioplasty (BPA) and remains symptomatic despite treatments with PDE5i.
• Patients with established diagnosis of CTEPH who are symptomatic after Balloon pulmonary angioplasty (BPA)
• Patients who are on stable maximally tolerated dose of sildenafil for at least 6 weeks as monotherapy, or in combination with other pulmonary hypertension specific therapies
• WHO functional class III at screening
• Stable dose of diuretics (if used) for at least 30 days at screening
• No recent hospitalisation due to pulmonary hypertension or heart failure for at least 30 days